Nintedanib Plus Docetaxel as Second-Line Therapy in Patients with Non-Small-Cell Lung Cancer (NSCLC)- A Network Meta-Analysis vs. New Therapeutic Options
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2093
https://www.valueinhealthjournal.com/article/S1098-3015(16)33459-3/fulltext
Title :
Nintedanib Plus Docetaxel as Second-Line Therapy in Patients with Non-Small-Cell Lung Cancer (NSCLC)- A Network Meta-Analysis vs. New Therapeutic Options
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33459-3&doi=10.1016/j.jval.2016.09.2093
First page :
A711
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1982